Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Carcinoma 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × molibresib × CNS × Clear all
NCT01587703 2020-03-16

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

GlaxoSmithKline

Phase 1 Completed
196 enrolled 78 charts
CNSPlasma cellThoracic

Carcinoma, Multiple Myeloma, Neoplasms, Neuroblastoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡